A Novel Gene Pair CSTF2/DPE2A Impacts Prognosis and Cell Cycle of Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) related hepatocellular carcinoma. Open Virol J. 2018;12(1):26–32. doi:10.2174/1874357901812010026
   PubMedGoogle Scholar
• Chen Z, Xie H, Hu M, et al. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.
   PubMed Web of Science ®Google Scholar
• Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23(29):5282–5294. doi:10.3748/wjg.v23.i29.5282
   PubMed Web of Science ®Google Scholar
• Schweitzer A, Horn J, Mikolajczyk RT, et al. 1Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555. doi:10.1016/S0140-6736(15)61412-X
   PubMed Web of Science ®Google Scholar
• Wild CP, Miller JD, Groopman JD. CHAPTER 3. Effects of aflatoxins on aflatoxicosis and liver cancer. In: Mycotoxin Control in Low- and Middle-Income Countries. Lyon (FR); 2015:13.
   Google Scholar
• Kanda T, Goto T, Hirotsu Y, et al. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci. 2019;20(6):1358. doi:10.3390/ijms20061358
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9
   PubMed Web of Science ®Google Scholar
• Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–137. doi:10.1007/s12072-018-9919-1
   PubMed Web of Science ®Google Scholar
• Li Y, Zeng X. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma. Front Pharmacol. 2022;13:1081952. doi:10.3389/fphar.2022.1081952
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li X, Long G, et al. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma. Front Immunol. 2022;13:994259. doi:10.3389/fimmu.2022.994259
   PubMedGoogle Scholar
• Kang C, Jia X, Liu H. Development and validation of a RNA binding protein gene pair-associated prognostic signature for prediction of overall survival in hepatocellular carcinoma. Biomed Eng Online. 2020;19(1):68. doi:10.1186/s12938-020-00812-0
   PubMed Web of Science ®Google Scholar
• Luo Y, Liu F, Han S, et al. Autophagy-related gene Pairs signature for the prognosis of hepatocellular carcinoma. Front Mol Biosci. 2021;8:670241. doi:10.3389/fmolb.2021.670241
   PubMed Web of Science ®Google Scholar
• Sun XY, Yu S-Z, Zhang H-P, et al. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma. Cancer Med. 2020;9(8):2868–2878. doi:10.1002/cam4.2921
   PubMed Web of Science ®Google Scholar
• Takagaki Y, MacDonald CC, Shenk T, et al. The human 64-kDa polyadenylylation factor contains a ribonucleoprotein-type RNA binding domain and unusual auxiliary motifs. Proc Natl Acad Sci U S A. 1992;89(4):1403–1407. doi:10.1073/pnas.89.4.1403
   PubMed Web of Science ®Google Scholar
• Monarez RR, MacDonald CC, Dass B. Polyadenylation proteins CstF-64 and τCstF-64 exhibit differential binding affinities for RNA polymers. Biochem J. 2007;401(3):651–658. doi:10.1042/BJ20061097
   PubMedGoogle Scholar
• MacDonald CC, Wilusz J, Shenk T. The 64-kilodalton subunit of the CstF polyadenylation factor binds to pre-mRNAs downstream of the cleavage site and influences cleavage site location. Mol Cell Biol. 1994;14(10):6647–6654. doi:10.1128/mcb.14.10.6647-6654.1994
   PubMed Web of Science ®Google Scholar
• Yao C, Biesinger J, Wan J, et al. Transcriptome-wide analyses of CstF64-RNA interactions in global regulation of mRNA alternative polyadenylation. Proc Natl Acad Sci U S A. 2012;109(46):18773–18778. doi:10.1073/pnas.1211101109
   PubMed Web of Science ®Google Scholar
• Chen Z, Hao W, Tang J, et al. CSTF2 promotes hepatocarcinogenesis and hepatocellular carcinoma progression via Aerobic glycolysis. Front Oncol. 2022;12:897804. doi:10.3389/fonc.2022.897804
   PubMed Web of Science ®Google Scholar
• Zhang MH, Liu J. Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3’-kinase/protein kinase B/mammalian target of rapamycin pathway. Bioengineered. 2022;13(4):10047–10060. doi:10.1080/21655979.2022.2063100
   PubMed Web of Science ®Google Scholar
• Wang J, Wu M, Lin X, et al. Low-concentration oxygen/ozone treatment attenuated radiculitis and mechanical allodynia via PDE2A-cAMP/cGMP-NF- κ B/p65 signaling in chronic radiculitis rats. Pain Res Manag. 2018;2018:5192814. doi:10.1155/2018/5192814
   PubMed Web of Science ®Google Scholar
• He J, Zhao H, Deng D, et al. Screening of significant biomarkers related with prognosis of liver cancer by lncRNA-associated ceRNAs analysis. J Cell Physiol. 2020;235(3):2464–2477. doi:10.1002/jcp.29151
   PubMed Web of Science ®Google Scholar
• Chen L, Zhou J, Zhao Z, et al. Low Expression of Phosphodiesterase 2 (PDE2A) promotes the progression by regulating mitochondrial morphology and ATP content and predicts poor prognosis in hepatocellular carcinoma. Cells. 2022;12(1). doi:10.3390/cells12010068
   Web of Science ®Google Scholar
• Zhang W, Wan Y, Zhang Y, et al. CSTF2 acts as a prognostic marker correlated with immune infiltration in hepatocellular carcinoma. Cancer Manag Res. 2022;14:2691–2709. doi:10.2147/CMAR.S359545
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu Z, Wu D, et al. Single-cell RNA-Seq analysis reveals microenvironmental infiltration of plasma cells and hepatocytic prognostic markers in HCC with cirrhosis. Front Oncol. 2020;10:596318. doi:10.3389/fonc.2020.596318
   PubMed Web of Science ®Google Scholar
• Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019;7:e7132. doi:10.7717/peerj.7132
   PubMed Web of Science ®Google Scholar
• Wang Z, Teng D, Li Y, et al. A six-gene-based prognostic signature for hepatocellular carcinoma overall survival prediction. Life Sci. 2018;203:83–91. doi:10.1016/j.lfs.2018.04.025
   PubMed Web of Science ®Google Scholar
• Yang S, Zhou Y, Zhang X, et al. The prognostic value of an autophagy-related lncRNA signature in hepatocellular carcinoma. BMC Bioinform. 2021;22(1):217. doi:10.1186/s12859-021-04123-6
   PubMed Web of Science ®Google Scholar
• Liu Y, Wei X, Zhang X, et al. CT radiomics combined with clinical variables for predicting the overall survival of hepatocellular carcinoma patients after hepatectomy. Transl Oncol. 2022;26:101536. doi:10.1016/j.tranon.2022.101536
   PubMed Web of Science ®Google Scholar
• Job S, Rapoud D, Dos Santos A, et al. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Hepatology. 2020. Vol. 72(3):965–981.
   Google Scholar
• Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–1503. doi:10.1038/nm.2492
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor Microenvironment. Medicina. 2019;56(1):15. doi:10.3390/medicina56010015
   PubMed Web of Science ®Google Scholar
• Pottier C, Wheatherspoon A, Roncarati P, et al. The importance of the tumor microenvironment in the therapeutic management of cancer. Expert Rev Anticancer Ther. 2015;15(8):943–954. doi:10.1586/14737140.2015.1059279
   PubMed Web of Science ®Google Scholar
• Watnick RS. The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med. 2012;2(12):a006676. doi:10.1101/cshperspect.a006676
   PubMed Web of Science ®Google Scholar
• Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261–267. doi:10.1016/j.coi.2013.03.004
   PubMed Web of Science ®Google Scholar
• Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017;66(2):342–351. doi:10.1136/gutjnl-2015-310814
   PubMed Web of Science ®Google Scholar
• Zhu LY, Zhou J, Liu Y-Z, et al. 自然杀伤细胞在原发性肝细胞肝癌中的浸润及其与预后的关系 [Prognostic significance of natural killer cell infiltration in hepatocellular carcinoma]. Ai Zheng. 2009;28(11):1198–1202. Chinese. doi:10.5732/cjc.009.10284
   PubMedGoogle Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Mossanen JC, Kohlhepp M, Wehr A, et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4(+) T-cell-dependent control of senescence. Gastroenterology. 2019;156(6):1877–1889 e4. doi:10.1053/j.gastro.2019.01.247
   PubMed Web of Science ®Google Scholar
• Street SE, Trapani JA, MacGregor D, et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med. 2002;196(1):129–134. doi:10.1084/jem.20020063
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Y, Song Z, et al. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J Interferon Cytokine Res. 2015;35(4):273–280. doi:10.1089/jir.2014.0132
   PubMed Web of Science ®Google Scholar
• Huang R, Li Z, Zhu X, et al. Collagen type III alpha 1 chain regulated by GATA-binding protein 6 affects type II IFN response and propanoate metabolism in the recurrence of lower grade glioma. J Cell Mol Med. 2020;24(18):10803–10815. doi:10.1111/jcmm.15705
   PubMed Web of Science ®Google Scholar
• Abdul-Wahid A, Cydzik M, Prodeus A, et al. Induction of antigen-specific T H 9 immunity accompanied by mast cell activation blocks tumor cell engraftment. Int J Cancer. 2016;139(4):841–853. doi:10.1002/ijc.30121
   PubMed Web of Science ®Google Scholar
• Tu JF, Pan H-Y, Ying X-H, et al. Mast cells comprise the major of interleukin 17-producing cells and predict a poor prognosis in hepatocellular carcinoma. Medicine. 2016;95(13):e3220. doi:10.1097/MD.0000000000003220
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang L, Jiang Z, et al. TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression. Theranostics. 2019;9(20):5810–5827. doi:10.7150/thno.34973
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2”. TAN Cancer Cell. 2009;16(3):183–194. doi:10.1016/j.ccr.2009.06.017
   PubMed Web of Science ®Google Scholar
• Jiang H, Ning G, Wang Y, et al. Identification of an m6A-related signature as biomarker for hepatocellular carcinoma prognosis and correlates with sorafenib and anti-PD-1 immunotherapy treatment response. Dis Markers. 2021;2021:5576683. doi:10.1155/2021/5576683
   PubMed Web of Science ®Google Scholar
• Jiao X, Shu G, Liu H, et al. The diagnostic value of chemokine/chemokine receptor Pairs in hepatocellular carcinoma and colorectal liver metastasis. J Histochem Cytochem. 2019;67(5):299–308. doi:10.1369/0022155418824274
   PubMed Web of Science ®Google Scholar
• Gong Z, Zhang J, Guo W. Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer. Cancer Med. 2020;9(23):9052–9063. doi:10.1002/cam4.3505
   PubMed Web of Science ®Google Scholar
• Xiang S, Li J, Shen J, et al. Identification of prognostic genes in the tumor microenvironment of hepatocellular carcinoma. Front Immunol. 2021;12:653836. doi:10.3389/fimmu.2021.653836
   PubMed Web of Science ®Google Scholar
• Lin X, LI H-R, LIN X-F, et al. Silencing of Livin inhibits tumorigenesis and metastasis via VEGF and MMPs pathway in lung cancer. Int J Oncol. 2015;47(2):657–667. doi:10.3892/ijo.2015.3058
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang N, Liu P, et al. AMPK and Cancer. Exp Suppl. 2016;107:203–226. doi:10.1007/978-3-319-43589-3_9
   PubMedGoogle Scholar
• Murugan AK. mTOR: role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;59:92–111. doi:10.1016/j.semcancer.2019.07.003
   PubMed Web of Science ®Google Scholar
• Smith AJ, Smith LA. Viral Carcinogenesis. Prog Mol Biol Transl Sci. 2016;144:121–168.
   PubMed Web of Science ®Google Scholar
• Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264. doi:10.1016/j.cell.2019.01.021
   PubMed Web of Science ®Google Scholar
• Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71. doi:10.1186/s13045-019-0754-1
   PubMed Web of Science ®Google Scholar
• Li W, Saud SM, Young MR, et al. Targeting AMPK for cancer prevention and treatment. Oncotarget. 2015;6(10):7365–7378. doi:10.18632/oncotarget.3629
   PubMedGoogle Scholar
• Tessema M, Lehmann U, Kreipe H. Cell cycle and no end. Virchows Arch. 2004;444(4):313–323. doi:10.1007/s00428-003-0971-3
   PubMed Web of Science ®Google Scholar
• Zheng K, He Z, Kitazato K, et al. Selective autophagy regulates cell cycle in cancer therapy. Theranostics. 2019;9(1):104–125. doi:10.7150/thno.30308
   PubMed Web of Science ®Google Scholar
• Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. J Clin Oncol. 2017;35(25):2949–2959. doi:10.1200/JCO.2016.69.0032
   PubMed Web of Science ®Google Scholar
• De Mattia E, Cecchin E, Guardascione M, et al. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol. 2019;25(29):3870–3896. doi:10.3748/wjg.v25.i29.3870
   PubMed Web of Science ®Google Scholar
• Boland P, Wu J. Systemic therapy for hepatocellular carcinoma: beyond sorafenib. Chin Clin Oncol. 2018;7(5):50. doi:10.21037/cco.2018.10.10
   PubMed Web of Science ®Google Scholar